| Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease R Zeiser, N Polverelli, R Ram, SK Hashmi, R Chakraverty, JM Middeke, ... New England Journal of Medicine 385 (3), 228-238, 2021 | 291 | 2021 |
| Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years N Vianelli, F Palandri, N Polverelli, R Stasi, J Joelsson, E Johansson, ... haematologica 98 (6), 875, 2013 | 154 | 2013 |
| Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis F Palandri, M Breccia, M Bonifacio, N Polverelli, EM Elli, G Benevolo, ... Cancer 126 (6), 1243-1252, 2020 | 125 | 2020 |
| Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations L Pagano, A Busca, A Candoni, C Cattaneo, S Cesaro, R Fanci, G Nadali, ... Blood reviews 31 (2), 17-29, 2017 | 117 | 2017 |
| Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment‐related risk factors M Ruggeri, A Tosetto, F Palandri, N Polverelli, MG Mazzucconi, C Santoro, ... Journal of Thrombosis and Haemostasis 12 (8), 1266-1273, 2014 | 117 | 2014 |
| Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years F Palandri, N Polverelli, D Sollazzo, M Romano, L Catani, M Cavo, ... American Journal of Hematology 91 (4), E267-E272, 2016 | 103 | 2016 |
| Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response M Marangon, N Vianelli, F Palandri, MG Mazzucconi, C Santoro, ... European Journal of Haematology 98 (4), 371-377, 2017 | 100 | 2017 |
| Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis F Palandri, R Latagliata, N Polverelli, A Tieghi, M Crugnola, B Martino, ... Leukemia 29 (6), 1344-1349, 2015 | 91 | 2015 |
| Long‐term follow‐up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy F Palandri, L Catani, N Testoni, E Ottaviani, N Polverelli, M Fiacchini, ... American journal of hematology 84 (4), 215-220, 2009 | 82 | 2009 |
| Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation S Bernardi, M Malagola, C Zanaglio, N Polverelli, E Dereli Eke, M D’Adda, ... Cancer medicine 8 (5), 2041-2055, 2019 | 80 | 2019 |
| Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study F Palandri, N Polverelli, L Catani, E Ottaviani, M Baccarani, N Vianelli Annals of hematology 90, 933-938, 2011 | 80 | 2011 |
| Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis F Palandri, GA Palumbo, M Bonifacio, M Tiribelli, G Benevolo, B Martino, ... Oncotarget 8 (45), 79073, 2017 | 79 | 2017 |
| Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients N Polverelli, M Breccia, G Benevolo, B Martino, A Tieghi, R Latagliata, ... American journal of hematology 92 (1), 37-41, 2017 | 75 | 2017 |
| Decreased expression of indoleamine 2, 3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia L Catani, D Sollazzo, S Trabanelli, A Curti, C Evangelisti, N Polverelli, ... Annals of hematology 92, 67-78, 2013 | 74 | 2013 |
| Pregnancy complications predict thrombotic events in young women with essential thrombocythemia ML Randi, I Bertozzi, E Rumi, C Elena, G Finazzi, N Vianelli, N Polverelli, ... American journal of hematology 89 (3), 306-309, 2014 | 64 | 2014 |
| Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases E Sant'Antonio, P Guglielmelli, L Pieri, M Primignani, ML Randi, ... American journal of hematology 95 (2), 156-166, 2020 | 60 | 2020 |
| JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients F Palandri, E Ottaviani, F Salmi, L Catani, N Polverelli, M Fiacchini, ... Leukemia & lymphoma 50 (2), 247-253, 2009 | 60 | 2009 |
| A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera F Lussana, A Carobbio, ML Randi, C Elena, E Rumi, G Finazzi, I Bertozzi, ... British journal of haematology 167 (4), 541-546, 2014 | 59 | 2014 |
| Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies … N Polverelli, K Mauff, N Kröger, M Robin, D Beelen, D Beauvais, ... American journal of hematology 96 (1), 69-79, 2021 | 52 | 2021 |
| A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis M Maffioli, B Mora, S Ball, A Iurlo, EM Elli, MC Finazzi, N Polverelli, ... Blood advances 6 (6), 1855-1864, 2022 | 51 | 2022 |
